Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 134

1.

The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis.

Jhaveri KS, Hosseini-Nik H, Sadoughi N, Janssen H, Feld JJ, Fischer S, Menezes R, Cheung AC.

Eur Radiol. 2018 Jul 26. doi: 10.1007/s00330-018-5619-4. [Epub ahead of print]

PMID:
30051141
2.

Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis.

Friedrich K, Baumann C, Wannhoff A, Rupp C, Mehrabi A, Weiss KH, Gotthardt DN.

J Gastrointestin Liver Dis. 2018 Jun;27(2):145-150. doi: 10.15403/jgld.2014.1121.272.cho.

3.

An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis.

Schulze J, Lenzen H, Hinrichs JB, Ringe B, Manns MP, Wacker F, Ringe KI.

Clin Gastroenterol Hepatol. 2018 Jul 11. pii: S1542-3565(18)30497-X. doi: 10.1016/j.cgh.2018.05.011. [Epub ahead of print]

PMID:
29775791
4.

Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients.

Zhang Y, Shi Y, Wu R, Wang X, Gao X, Niu J.

Eur J Gastroenterol Hepatol. 2018 Jun;30(6):682-686. doi: 10.1097/MEG.0000000000001100.

PMID:
29462025
5.

Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study.

Kogiso T, Egawa H, Teramukai S, Taniai M, Hashimoto E, Tokushige K, Sakisaka S, Sakabayashi S, Yamamoto M, Umeshita K, Uemoto S.

Hepatol Commun. 2017 May 16;1(5):394-405. doi: 10.1002/hep4.1037. eCollection 2017 Jul.

6.

Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.

Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, Norman GL, Veres G, Par G, Par A, Szalay F, Lakatos PL, Antal-Szalmas P, Papp M.

Sci Rep. 2018 Jan 10;8(1):399. doi: 10.1038/s41598-017-18622-1.

7.

Regulatory T cells with a defect in inhibition on co-stimulation deteriorated primary biliary cholangitis.

Chen J, Hou X, Jia H, Cui G, Wu Z, Wang L, Lu C, Wu W, Wei Y, Uede T, Li L, Lian Z, Diao H.

Oncotarget. 2017 Nov 26;8(65):108406-108417. doi: 10.18632/oncotarget.22658. eCollection 2017 Dec 12.

8.

Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.

Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M.

World J Gastroenterol. 2017 Aug 7;23(29):5412-5421. doi: 10.3748/wjg.v23.i29.5412.

9.

Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort.

Lin L, Piao M, Jiang X, Lv H, Zhao N, Yang F, Sun C.

BMJ Open. 2017 Jul 12;7(7):e015304. doi: 10.1136/bmjopen-2016-015304.

10.

Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function.

Kummen M, Vesterhus M, Trøseid M, Moum B, Svardal A, Boberg KM, Aukrust P, Karlsen TH, Berge RK, Hov JR.

United European Gastroenterol J. 2017 Jun;5(4):532-541. doi: 10.1177/2050640616663453. Epub 2016 Aug 2.

11.

Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.

Melchor-Mendoza YK, Martínez-Benítez B, Mina-Hawat A, Rodríguez-Leal G, Duque X, Moran-Villota S.

Ann Hepatol. 2017 May - Jun;16(3):430-435. doi: 10.5604/16652681.1235486.

12.

Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.

Vesterhus M, Holm A, Hov JR, Nygård S, Schrumpf E, Melum E, Thorbjørnsen LW, Paulsen V, Lundin K, Dale I, Gilja OH, Zweers SJLB, Vatn M, Schaap FG, Jansen PLM, Ueland T, Røsjø H, Moum B, Ponsioen CY, Boberg KM, Färkkilä M, Karlsen TH, Lund-Johansen F.

J Hepatol. 2017 Jun;66(6):1214-1222. doi: 10.1016/j.jhep.2017.01.019. Epub 2017 Feb 2.

PMID:
28161472
13.

A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.

Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z.

J Gastrointestin Liver Dis. 2016 Dec;25(4):457-464. doi: 10.15403/jgld.2014.1121.254.rah.

14.

Early Peribiliary Hyperenhancement on MRI in Patients with Primary Sclerosing Cholangitis: Significance and Association with the Mayo Risk Score.

Ni Mhuircheartaigh JM, Lee KS, Curry MP, Pedrosa I, Mortele KJ.

Abdom Radiol (NY). 2017 Jan;42(1):152-158. doi: 10.1007/s00261-016-0847-z.

PMID:
27472938
15.

Impact of previous cyst-enterostomy on patients' outcome following resection of bile duct cysts.

Ouaissi M, Kianmanesh R, Ragot E, Belghiti J, Majno P, Nuzzo G, Dubois R, Revillon Y, Cherqui D, Azoulay D, Letoublon C, Pruvot FR, Paye F, Rat P, Boudjema K, Roux A, Mabrut JY, Gigot JF.

World J Gastrointest Surg. 2016 Jun 27;8(6):427-35. doi: 10.4240/wjgs.v8.i6.427.

16.

Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis.

Gauss A, Sauer P, Stiehl A, Rupp C, Krisam J, Leopold Y, Kloeters-Plachky P, Stremmel W, Gotthardt D.

Medicine (Baltimore). 2016 Apr;95(17):e3510. doi: 10.1097/MD.0000000000003510.

17.

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.

Yin Q, Li J, Xia Y, Zhang R, Wang J, Lu W, Zhou Y, Zheng Y, Abudumijiti H, Chen R, Chen K, Li S, Liu T, Wang F, Lu J, Zhou Y, Guo C.

Drug Des Devel Ther. 2015 Sep 30;9:5407-19. doi: 10.2147/DDDT.S92041. eCollection 2015. Review. Erratum in: Drug Des Devel Ther. 2015;9:5947.

18.

Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease.

Wunsch E, Milkiewicz M, Wasik U, Trottier J, Kempińska-Podhorodecka A, Elias E, Barbier O, Milkiewicz P.

Sci Rep. 2015 Aug 21;5:13462. doi: 10.1038/srep13462.

19.

Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC).

Hinrichs H, Hinrichs JB, Gutberlet M, Lenzen H, Raatschen HJ, Wacker F, Ringe KI.

Eur Radiol. 2016 Apr;26(4):1116-24. doi: 10.1007/s00330-015-3913-y. Epub 2015 Jul 24.

PMID:
26205638
20.

Individuals with Primary Sclerosing Cholangitis Have Elevated Levels of Biomarkers for Apoptosis but Not Necrosis.

Masuoka HC, Vuppalanchi R, Deppe R, Bybee P, Comerford M, Liangpunsakul S, Ghabril M, Chalasani N.

Dig Dis Sci. 2015 Dec;60(12):3642-6. doi: 10.1007/s10620-015-3805-7. Epub 2015 Jul 21.

Supplemental Content

Loading ...
Support Center